We are very excited about the role Synvista has to play in fulfilling important, unmet medical needs in diabetic and other patients as we advance our pipeline through development and into commercialization.
Thank you for your continued interest in Synvista. I look forward to keeping you apprised of our progress.
Noah Berkowitz, M.D., Ph.D.
President and Chief Executive Officer
About Synvista Therapeutics
Synvista Therapeutics is a biopharmaceutical company developing diagnostics and drugs to diagnose, treat and prevent cardiovascular disease in people with diabetes. The Company has developed a clinical diagnostic test for Hp2-2 Diabetes. The genetic or protein form of this test can be used to identify diabetic patients at high risk for cardiovascular complications. These patients may benefit from a particular formulation of vitamin E. The Company is also developing a kit to measure CML (carboxy-methyllysine), another potential cardiovascular risk marker.
Synvista Therapeutics is developing oral antioxidant drugs to treat the
HDL dysfunction seen in Hp2-2 Diabetes, a disease affecting almost 7
million patients in the United States. The Company is also developing
alagebrium, a proposed breaker of advanced glycation endproducts (AGEs) for
the treatment of systolic and diastolic heart failure. Diastolic heart
failure represents a rapidly growing market of unmet medical need,
particularly common among diabetic patients. Alagebrium has demonstrated
relevant clinical activity in two Phase 2 clinical trials in heart failure,
as well as in animal models of heart failure and nephropathy, among others.
Alagebrium has been tested in approximately 1,000 patients in multiple
Phase 1 and Phase 2 clinical
|SOURCE Synvista Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved